• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Bausch Health's Charts Continue to Look Out of Focus

The technical signals of the diversified health care company still don't inspire confidence to establish long positions in its stock at this time.
By BRUCE KAMICH
Mar 23, 2022 | 07:51 AM EDT
Stocks quotes in this article: BHC

In his Executive Decision segment of Tuesday's "Mad Money" program, host Jim Cramer spoke with Joe Papa, chairman and CEO of Bausch Health (BHC) , which plans to split itself into three companies but has yet to pull the trigger.

Papa said the split is still happening, but Bausch Health management is balancing the need to move quickly with the desire to maximize value for shareholders, something that's more difficult to gauge in volatile markets. They're not looking for perfect market conditions, he said, but they are looking for "ideal" conditions before executing the transaction.

In the meantime, Papa noted that Bausch Health is generating a lot of cash, which it is using to pay down debt. He was confident that all three of Bausch Health's new entities will create a lot of value for shareholders.

I looked at the charts of BHC on Feb. 22 before it reported fourth-quarter results and wrote, "I have no special knowledge of what BHC is going to report to analysts and shareholders, but the charts and indicators are not yet constructive. Continue to avoid the long side."

Let's check on the charts of BHC again.

In this updated daily bar chart of BHC, below, we can see that prices are still in a downtrend from late April. Prices are just below the declining 50-day moving average line. The slope of the slower-to-react 200-day line is negative. The trading volume has been very active since the beginning of the year and tells me that some traders have been voting with their feet. The On-Balance-Volume (OBV) line shows a decline from early January to the middle of March. The OBV line may be starting to improve but it is a little early to declare that buyers have become more aggressive. The Moving Average Convergence Divergence (MACD) oscillator is below the zero line in sell territory, but the two moving averages that comprise this indicator have crossed to the upside for a cover shorts buy signal.

In this weekly Japanese candlestick chart of BHC, below, we can see that prices are in a longer-term decline from early 2021. BHC is trading below the declining 40-week moving average line. A lower shadow earlier this month shows us some promise that traders are rejecting the lows. This could be the start of a bottoming process. The OBV line has been weakish since last March. The MACD oscillator is bearish but has narrowed in recent weeks.

In this daily Point and Figure chart of BHC, below, we can see a potential downside price target of $20.

In this weekly Point and Figure chart of BHC, below, we used close-only price data. Here the software is projecting a potential price objective in the $16 area.

Bottom line strategy: So far our recommendation to avoid the long side of BHC has paid off. Prices may change direction from down to sideways but that is not quite enough to get me to recommend purchase of BHC.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Healthcare | Pharmaceuticals | Mad Money | Executive Interview

More from Stocks

Stay Guarded Amid Rally's Rotation

James "Rev Shark" DePorre
May 23, 2022 4:41 PM EDT

Stocks spin, and that makes the market picture rather murky.

Dare I Recommend a Retail Name Like American Eagle Outfitters?

Bruce Kamich
May 23, 2022 3:15 PM EDT

Let's check out the charts.

Gravity Is Pulling on Apple

Mark Sebastian
May 23, 2022 2:32 PM EDT

Here's where I see AAPL going and how to play it.

Look for General Motors Shares to Restart Their Uptrend

Bruce Kamich
May 23, 2022 2:10 PM EDT

Why aggressive traders could get behind the GM wheel again.

Alibaba Is Sold out on the Downside

Bruce Kamich
May 23, 2022 1:26 PM EDT

China at a bearish extreme is an opportunity.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login